Skip to Main Content
CIMA Sciences
  • OWLiver®
  • Clinical Need
  • About
  • News & Events
  • Contact
  • check_circleOrder OWLiver® Test

Cima Sciences to exhibit at the 2025 AASLD The Liver Meeting

October 28, 2025

Cima Sciences is proud to exhibit at the 2025 AASLD The Liver Meeting in Washington, D.C. Along with Rubió Metabolomics, we are excited to connect with existing and new clients interested in the most comprehensive detection of all treatable stages of MASLD.

Come visit us at Booth# 761 to further discuss using OWLiver in your practice or clinical studies.

Additionally, we will presenting and co-presenting some exciting data within the Poster sessions. It is a great opportunity to meet with the presenters. Check out the poster presentations below:

-Maximizing the Diagnostic Yield of Non-Invasive Tests: Simultaneous Optimization of Key Performance Metrics for Fibrotic Liver Disease with a FIB-4 and MASEF (OWLiver) Strategy. Publication Number: 2077. Presentation date: Saturday 8th.

-Saroglitazar treatment reduced severity of MASLD phenotypes by lipidomic-based test OWLiver in subjects with MASLD in a 16-week phase 2 trial. Publication number: 4020. Presentation Date: Monday 10th. Poster of distinction.

Related Posts

All Posts

As Obesity Treatment Advances, Early Liver Disease Detection Matters More Than Ever

August 7, 2026

When Obesity Complicates Liver Disease Assessment

July 22, 2026

How OWLiver Delivers a Complete Picture of Liver Health

February 5, 2026

Advancing Non-Invasive Diagnostics.

info
Contact Us

24 Greenway Plaza,

Suite 1800

Houston, TX 77046

email

info@cimasciences.com

phone

Tel. 888-968-9912

  • LinkedIn
check_circle
Order OWLiver® Test

OWLiver® is a non-invasive blood test to assess MASLD. It analyzes a panel of biomarkers through metabolomics methodology.

Order OWLiver® Test

© 2026 CIMA Sciences

Site by Metropolis